Table III.
Tumor type | Cell lines | GD2 expression (MFI) |
Maximum level of lysis |
Tumor cytotoxicity (EC50)(nM) |
---|---|---|---|---|
Melanoma | SKMEL-1 | 38 | 36% | 0.01 |
Neuroblastoma | LAN-1 | 201 | 52% | 0.04 |
Neuroblastoma | NMB-7 | 127 | 60% | 0.05 |
Melanoma | M14 | 50 | 50% | 0.09 |
Neuroblastoma | BE(1)N | 94 | 46% | 0.17 |
Neuroblastoma | IMR-32 | 128 | 58% | 0.20 |
Melanoma | HT-144 | 13 | 35% | 0.48 |
Small cell lung cancer |
NCI-H524 | 66 | 58% | 0.61 |
Neuroblastoma | SKNJC2 | 6 | 25% | 0.86* |
Melanoma | SKMEL28 | 8 | 28% | 2.20* |
small cell lung cancer |
NCI-H69 | 27 | 39% | 3.16* |
Breast Cancer | MDA-MB-468 | 6 | 13% | 3.89* |
small cell lung cancer |
NCI-H196 | 8 | 7% | > 185 |
small cell lung cancer |
NCI-H345 | 7 | 2% | >185 |
GD2 expression of cell lines were expressed as mean fluoresce intensity. Cytotoxicity assays (51Cr release) were carried out with cultured T cells at E: T ratio of 10:1. Maximum level of lysis was measured at a 18.5 nM concentration of 5HLDS(15)BA (Y). EC50 was calculated using Sigma plot 8.0.
Numbers were extrapolated by Sigma plot 8.0.